News
-
CTN study tests new drug for the first time in people living with HIV
The drug works against CMV, a common virus that may be a main cause of inflammation and health problems in people living with HIV
-
Guest blog: Dr. Stéphane Isnard
Meet Dr. Stéphane Isnard, a CTN postdoctoral fellow who is investigating the role gut mucosa and gut microbiota play in HIV physiopathology
Resources
Our Resource Library is a place to share documents, videos, and training resources about HIV and STBBI research and related topics.
Studies
The CTN+ supports clinical trials, implementation science projects, and non-interventional research of the highest scientific and ethical standards.
-
CTN 247: Canadian cohort of HIV+ slow progressors
A study of host and viral factors associated with disease progression in long term HIV infected subjects
-
CTN 281: EPIC 4 Study
Effectiveness of early treatment with anti-retroviral therapy in children with HIV
-
CTN 239: Phase II study of AGS-004 an immunotherapeutic agent in combination with ART followed by ART interruption
A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption: Trial results
-
CTN 229: Effect of AGS-004 immunotherapeutic agent in HIV-positive people on HAART
A pilot study (Phase I/II) testing the immunologic activity and safety of AGS-004, an autologous HIV immunotherapeutic, in HIV-infected adults on HAART: Trial results
-
CTN 256: Phase IIB study of efficacy and safety of AGS-004
A randomized, double blind, phase IIB study testing the efficacy and safety of AGS-004 on host control of HIV replication during analytical treatment interruption: Trial results
Publications
Our researchers and trainees have produced hundreds of peer-reviewed publications in a wide range of HIV- and STBBI-related areas.